Showing 203 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

Does six-monthly PrEP have a future following the collapse of global HIV funding?

News
23 July 2025
Injectable & long-acting PrEP

Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding

News
18 July 2025
Injectable & long-acting PrEP

Once-monthly oral PrEP moves into late-stage trials

News
17 July 2025
PrEP science

HIV PrEP Study Finds Modest Bone Loss on FTC/TDF Compared to Cabotegravir

Editor's pick
TheBodyPro
16 July 2025
Injectable & long-acting PrEP

WHO recommends injectable lenacapavir for HIV prevention

Editor's pick
World Health Organization
16 July 2025
Injectable & long-acting PrEP

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

Editor's pick
Merck press release
16 July 2025
Injectable & long-acting PrEP

New Analysis Exposes Path to Affordable Lenacapavir for HIV Prevention

Editor's pick
ITPC Global
16 July 2025
Injectable & long-acting PrEP

Global Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low- and Middle-Income Countries

Editor's pick
Global Fund News Releases
10 July 2025
Injectable & long-acting PrEP

Gilead to provide HIV prevention drug to 2 million people in lower-income countries at cost

Editor's pick
STAT (requires free registration)
10 July 2025
Pharmaceutical industry

Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access

Editor's pick
Médecins Sans Frontières
7 July 2025
Injectable & long-acting PrEP

Will long-lasting HIV preventive be a game changer—or a missed opportunity?

Editor's pick
Science Magazine
24 June 2025
Injectable & long-acting PrEP

HIV protection with just two shots a year: FDA approves Gilead drug

Editor's pick
STAT
19 June 2025
Injectable & long-acting PrEP

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Editor's pick
Gilead Sciences press release
19 June 2025
Pharmaceutical industry

FDA approves twice-yearly shot of Gilead drug for HIV prevention

Editor's pick
BioPharma Dive
19 June 2025
Injectable & long-acting PrEP

‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers

Editor's pick
The Guardian
17 June 2025
Injectable & long-acting PrEP

New Report: Getting PrEP Rollout Right This Time

Editor's pick
AVAC
12 June 2025
Injectable & long-acting PrEP

Uncertain road ahead for lenacapavir, a new ‘breakthrough’ HIV prevention drug

Editor's pick
Positively Aware
5 June 2025
Injectable & long-acting PrEP

Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty

Editor's pick
Reuters
2 June 2025
Access to healthcare

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire

News
10 April 2025
Finance & funding

HIV testing requirements must be simplified for injectable PrEP to have a future

News
21 March 2025
Injectable & long-acting PrEP

Injectable PrEP use leads to zero new HIV infections among gay, trans and non-binary Brazilians

News
17 March 2025
Injectable & long-acting PrEP

Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise

News
17 March 2025
Injectable & long-acting PrEP

Annual jab for HIV protection passes trial hurdle

Editor's pick
BBC News
17 March 2025
Injectable & long-acting PrEP

Cabotegravir injections for PrEP

About HIV
July 2024